Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & EMBASE  
     Home | Subscribe | Feedback  

[Download PDF
Year : 2010  |  Volume : 56  |  Issue : 2  |  Page : 163-167  


M Bhattacharya1, K Rajeshwari1, B Dhingra2,  
1 Department of Pediatrics, Maulana Azad Medical College & Lok Nayak Hospital, New Delhi, India
2 Department of Hematology & Oncology, All India Institute of Medical Sciences, Delhi, India

Correspondence Address:
M Bhattacharya
Department of Pediatrics, Maulana Azad Medical College & Lok Nayak Hospital, New Delhi


Posaconazole is a novel second-generation Triazole oral antifungal agent. It is highly effective in the prophylaxis of invasive fungal infections in immunocompromised patients. It is used as a first-line agent as well as for salvage therapy in invasive fungal infections including aspergillosis, oropharyngeal and esophageal candidiasis. It has a good adverse effect profile. With the rising incidence of invasive fungal infections due to the HIV pandemic and medical advancements in transplantation and cancer therapy, these features make posaconazole a valuable addition in the family of antifungal agents.

How to cite this article:
Bhattacharya M, Rajeshwari K, Dhingra B. Posaconazole.J Postgrad Med 2010;56:163-167

How to cite this URL:
Bhattacharya M, Rajeshwari K, Dhingra B. Posaconazole. J Postgrad Med [serial online] 2010 [cited 2023 Sep 22 ];56:163-167
Available from:

Full Text

Invasive fungal infections (IFI) are a major cause of morbidity and mortality in cancer patients and hematopoietic stem cell transplant (HSCT) recipients, HIV infection and other immunosuppressed patients. Moreover, IFI caused by Candida species other than Candida albicans and other emerging fungi in these patient subgroups are often resistant to conventional antifungal agents.

At present, four classes of antifungal agents are approved for use in IFI: the polyenes (e.g. Amphotericin B), the azoles (e.g. itraconazole, fluconazole and voriconazole), flucytosine and the echinocandins (e.g. caspofungin anidula fungin). [1],[2] These agents have a high failure rate ranging from 40 to 70%. [3],[4],[5],[6] Moreover, increasing use of these agents has led to the emergence of resistance against them.

In this scenario, posaconazole, a second-generation triazole, is a welcome addition to the battery of available antifungal agents with its broad-spectrum and potent activity against common as well as rare but emerging fungal pathogens resistant to standard antifungal therapy. This article briefly reviews the clinical pharmacology, therapeutic indications, an efficacy and safety of this drug.

 Antifungal spectrum

Activity against yeasts

Posaconazole is more active than itraconazole and fluconazole against Candida species and Cryptococcus neoformans.[7],[8],[9] Its activity against Candida species is comparable to voriconazole. [9] It inhibits most fluconazole-resistant Candida (barring Candida glabrata and Candida pelliculosa) and Cryptococcus neoformans isolates. [9] Posaconazole has also exhibited fungistatic activity against Rhodotorula and Trichosporon species. [7]

Activity against moulds

Posaconazole is the most active triazole against filamentous fungi. It is 4 to 16 times more active than Amphotericin B against Aspergillus [10] It is also active against Aspergillus fumigatus resistant to itraconazole, voriconazole and Amphotericin B. [11]

Posaconazole is also active against Fusarium species. [12] It is less active than Amphotericin B, more active than voriconazole and comparable to itraconazole in zygomycosis. [13]

Activity against endemic fungi

Posaconazole shows high in vitro activity against Histoplasma capsulatum, Blastomyces dermatidis and Coccidioides and less activity against Sporothrix schenckii.[14],[15]

Resistant fungal isolates (namely Candida and Aspergillus spp.) have been reported in patients on posaconazole prophylaxis. These isolates show reduced susceptibility to other triazoles signifying cross-resistance and warrants further study. [16]

[Table 1] summarizes the differences between posaconazole and other antifungals



Due to its lipophilicity, posaconazole does not have a solubilized intravenous formulation and is administered orally. Single doses exceeding 800 mg are not fully absorbed. [17] Twelve hourly and six hourly dosing intervals increase bioavailability by 98 and 220%, respectively. [18] The suspension form has better bioavailability as compared to the tablet form. [19] Concomitant intake with high-fat and non-fat meals causes four and 2.5 times increases in bioavailability, respectively. [19] Absorption is increased with concomitant intake of proton pump inhibitors. [20]


Posaconazole has a large volume of distribution (~1800 mL) and is highly plasma protein bound (>95%) suggesting extensive tissue distribution. [21],[22]

Metabolism and excretion

Majority of the administered dose is excreted unchanged (66%) in the feces (77%) and urine (14%) and only a small fraction is glucuronized by the UGT1A4 pathway. [22] Posaconazole has a long elimination half-life (20-66 h) and it reaches steady-state after 10 days of therapy. [21]


Posaconazole has structural similarity with itraconazole but with fluorine substituents in place of chlorine and a furan ring in place of dioxolane ring. By inhibiting lanosterol 14α-demethylase (CYP51), it leads to ergosterol depletion and causes accumulation of methylated sterol precursors, which cause inhibition of fungal cell growth and fungal cell death. [23]

 Clinical Efficacy

Posaconazole has been evaluated in a number of multicenter randomized controlled trials.

Prophylaxis of IFI

Posaconazole was compared with fluconazole for the prophylaxis of IFI in patients with graft versus host disease (GVHD) on high-dose immunosuppressive therapy and was found to be equally effective in preventing all IFI and better in preventing aspergillosis. [24] In another study, in patients with acute myeloid leukemia with severe chemotherapy-induced neutropenia, posaconazole group had lower incidence of breakthrough IFI as well as aspergillosis as compared to fluconazole and itraconazole. [25]

Oropharyngeal and esophageal candidiasis

Posaconazole was non-inferior to fluconazole in HIV positive patients with esophageal candidiasis. [26] It also had high cure rates (75-85%) in the treatment of azole-resistant esophageal and/or oropharyngeal candidiasis in HIV positive patients in two different studies. [27],[28]

Invasive fungal infections

Posaconazole was used as salvage therapy in patients with invasive aspergillosis refractory or intolerant to conventional antifungals. The control group received Amphotericin B, itraconazole or a combination of both. Some external controls also received voriconazole and echinocandins as salvage therapy. Posaconazole was concluded to be an effective option in the salvage therapy of invasive aspergillosis. [29] A retrospective study to evaluate the role of posaconazole as salvage therapy versus Amphotericin B and caspofungin favored posaconazole both in response rates and mortality. [30]

Posaconazole was also found to be effective as salvage therapy in zygomycosis resistant to various formulations of Amphotericin B. [31],[32]

Other therapeutic indications under study

Despite poor penetration into the CSF, posaconazole has been found to be effective in Cryptococcal meningitis and other CNS fungal infections either alone or in combination with other antifungal agents. [33] Other therapeutic indications under study are refractory histoplasmosis, coccidioidomycosis and invasive fusariosis. [34],[35],[36]

[Table 2] lists the details of various clinical efficacy trials of posaconazole.

In light of the above studies, posaconazole is currently indicated in the prophylaxis of IFI in immunosuppressed patients and in the treatment of oropharyngeal and esophageal candidiasis including azole-refractory cases. It is also given as salvage therapy in refractory IFI such as aspergillosis, zygomycosis, fusariosis, coccidioidomycosis and histoplasmosis. [16]

 Adverse Events, Contraindications and Drug Interactions

The most commonly encountered side effects with posaconazole are nausea (5%), vomiting (4%), diarrhea (3%) and headache (1%). Cases of QT prolongation (4%) and hepatotoxicity (1%) (mild to moderate elevations of ALT, AST, ALP and serum bilirubin and/or clinical hepatitis) have been reported in clinical trials, which were reversed upon discontinuation of the drug. [21]

Posaconazole is contraindicated in patients with hypersensitivity to the drug or any other constituent of the preparation. [21]

Posaconazole is an inhibitor of hepatic CYP3A4 and hence, increases whole blood concentrations of drugs that are metabolized by this enzyme (e.g. cyclosporine, tacrolimus, sirolimus). Plasma posaconazole levels are affected by agents that induce or inhibit hepatic glucuronidation (e.g. rifabutin, phenytoin). It should be co-administered with caution with agents that are hepatic CYP3A4 substrates and prolong the QTc interval (e.g. astemizole, cisapride, halofantrine, pimozide, quinidine, terfenadine). Its use is contraindicated in the USA and EU along with statins (hepatic CYP3A4 substrates) and ergot alkaloids. When administered with vinca alkaloids, some anti-retroviral agents (ritonavir, indinavir) and calcium channel blockers (hepatic CYP3A4 substrates), dose adjustments and frequent monitoring of adverse effects and therapeutic drug monitoring are warranted. [23],[37]

 Dosage and Administration

Posaconazole is available as a suspension (40 mg/mL). The dose for prophylaxis of IFI is 200 mg thrice a day. In oropharyngeal candidiasis, the dose is 100 mg twice a day on the first day of therapy followed by 100 mg once a day for 13 days. In azole-resistant oropharyngeal candidiasis, the dose is 400 mg twice daily. The duration of therapy depends on the clinical response. For salvage therapy for refractory aspergillosis, posaconazole is given at a dose of 400 mg twice daily for a minimum of 6-12 weeks. To optimize its absorption from the gut, it should be taken with a fatty meal or liquid nutritional supplement. If this is not feasible, an alternative antifungal agent should be considered. [23],[16] An intravenous formulation is being developed. [38]

Dose adjustment in special populations

No dose adjustment is required in the geriatric or adolescent population or based on race or sex. The safety and efficacy of posaconazole have not been established in children less than 13 years of age. Hence, no dosing regime is available for this age group. [16]

Unlike other azoles, dose reduction is not necessary in renal impairment or hepatic insufficiency. The drug is not eliminated in hemodialysis. [23]

The drug belongs to pregnancy risk category C. Its excretion in breast milk is not known and is to be used only if the potential benefit to the mother outweighs the risk to the baby. [23]

Posaconazole absorption is affected by concomitant diet, gastrointestinal disorders like mucositis and diarrhea and gastric pH. It interacts with antivirals (ritonavir, efavirenz), chemotherapeutic agents (vincristine), immunosuppressants (cyclosporine, sirolimus) and benzodiazepines (midazolam). Moreover, it has been reported that average plasma posaconazole concentrations were related to the efficacy of prophylaxis. However, lack of data on a target drug concentration makes recommendation for Role of therapeutic drug monitoring difficult. TDM may be considered in failing therapy, infection of sanctuary sites, refractory organisms, gastrointestinal disorders and inability to ingest high fat meals. [37]

In conclusion, posaconazole is a new oral, broad spectrum, triazole antifungal agent. It is currently approved for prophylaxis and treatment of IFI and treatment of azole sensitive and refractory esophageal and oropharyngeal candidiasis. To prevent emergence of resistance to this valuable and novel agent it should be reserved for salvage therapy of infections resistant to conventional antifungal agents in high-risk immunocompromised patients.


1Denning DW. Echinocandin antifungal drugs. Lancet 2003;362:1142-51.
2Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents : pharmacokinetics, safety and efficacy. Drugs 2004;64:1997-2020.
3Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Medicine (Baltimore) 2000;79:250-60.
4Antoniadou A, Torres HA, Lewis RE, Thornby J, Bodey GP, Tarrand JP, et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) 2003;82:309-21.
5Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630-37.
6Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, et al. Efficacy and toxicity of caspofungin in combination with liposomal Amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003;98:292-9.
7Barchiesi F, Arzeni D, Fothergill AW, Di Francesco LF, Caselli F, Rinaldi MG, et al. In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob Agents Chemother 2000;44:226-9.
8Pfaller MA, Messer SA, Hollis RJ, Jones RN. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 2001;45:2862-64.
9Pfaller MA, Messer SA, Boyken L, Hollis RJ, Rice C, Tendolkar S, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004;48:201-05.
10Marco F, Pfaller MA, Messer SA, Jones RN. In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi. Mycopathologia 1998;141:73-7.
11Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to Amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 2000;46:229-34.
12Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob Agents Chemother 2002;46:3298-300.
13Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, Amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002;46:1581-2.
14Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003;20:121-36.
15Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998;36:2950-6.
16Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH. Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother 2008;42:1429-38.
17Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003;47:2788-95.
18Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005;44:211-20.
19Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004;57:218-22.
20Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR. Omeprazole significantly reduces posaconazole serum trough level. Clin Infect Dis 2009;48:839.
21Product information. Noxafil (posaconazole). Kenilworth, NJ: Schering Corporation; 2006.
22Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004;48:3543-51.
23Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005;5:775-85.
24Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-47.
25Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59.
26Vazquez JA, Skiest DJ, Nieto L, Northland R, Sanne I, Gogate J, A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006;42:1179-86.
27Vazquez JA, Skiest DJ, Tissot-Dupont H, Lennox JL, Boparai N, Isaacs R. Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection. HIV Clin Trials 2007;8:86-97.
28Skiest DJ, Vazquez JA, Anstead GM, Graybill JR, Reynes J, Ward D, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007;44:607-14.
29Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:2-12.
30Raad II, Hanna HA, Boktour M, Jiang Y, Torres HA, Afif C, et al. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of Amphotericin B alone or in combination with caspofungin. Leukemia 2008;22:496-503.
31van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006;42:61-5.
32Greenberg RN, Anstead G, Herbrecht R. Posaconazole experience in the treatment of zygomycosis. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; Chichago, IL, USA; 2003.
33Pitisuttithum P, Negroni R, Graybill JR, Bustamante B, Pappas P, Chapman S, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005;56:745-55.
34Clark B, Foster R, Tunbridge A, Green S. A case of disseminated histoplasmosis successfully treated with the investigational drug posaconazole. J Infect 2005;51:177-80.
35Anstead GM, Corcoran G, Lewis J, Berg D, Graybill JR. Refractory coccidioidomycosis treated with posaconazole. Clin Infect Dis 2005;40:1770-6.
36Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006;42:1398-403.
37Hope WW, Billaud EM, Lestner J, Denning DW. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis 2008;21:580-6.
38Frampton JE, Scott LJ. Posaconazole: a review of its use in the prophylaxis of invasive fungal infections. Drugs 2008;68:993-1016.

Friday, September 22, 2023
 Site Map | Home | Contact Us | Feedback | Copyright  and disclaimer